Aviptadil: meta-analysis of COVID-19 studies

All studies Mortality Serious outcomes Recovery RCTs RCT mortality Peer-reviewed All outcomes

Outcome (studies)

Improvement

Relative risk · 95% CI

All studies (3)−5%

Mortality (2)16%

Progression (2)15%

RCTs (3)−5%

RCT mortality (2)16%

Peer-reviewed (2)16%

Late (3)−5%

00.511.5+

← Aviptadil
reduces riskIncreased
risk →

.hmva--anim-stagger .hmva__row{opacity:1}.hmva--anim .hmva__shade{opacity:var(--shade-opacity)}.hmva--anim-stagger .est .ci{transform:translateY(-50%)}.hmva--anim-stagger .est .pt{transform:translate(-50%,-50%)}.hmva--anim-stagger .hmva__bar{transform:none}.hmva--anim-settle .est .pt{left:calc(min(var(--pt), 1.5) / var(--max) * 100%)}.hmva--anim-settle .est .ci{left:calc(var(--lo) / var(--max) * 100%);width:calc((var(--hi) - var(--lo)) / var(--max) * 100%)}.hmva--anim-settle .hmva__bar--drug{width:calc(min(1, var(--rr)) * 100%)}.hmva--anim-settle .hmva__bar--control{width:calc(min(1, 1 / var(--rr)) * 100%)}

.fp--anim .fp__study,.fp--anim .fp__sum,.fp--anim .fp__het,.fp--anim .fp__dia,.fp--anim .fp__verdict,.fp--anim .fp__pooled{opacity:1}.fp--anim .fp__ci{transform:none}.fp--anim .fp__pt{transform:translate(-50%,-50%)}.fp--anim .fp__plot::before{opacity:var(--shade-opacity)}.fp--anim-settle .fp__pt{left:calc(min(var(--pt),var(--max))/var(--max)*100%)}.fp--anim-settle .fp__ci,.fp--anim-settle .fp__dia{left:calc(var(--lo)/var(--max)*100%);width:calc((var(--hi) - var(--lo))/var(--max)*100%)}

c19early.org

October 2026

Aviptadil COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Gibbs (DB RCT)−79%1.79 · 1.12–2.94no recov.51 (n)67 (n)I-SPY Youssef (DB RCT)35%0.65 · 0.39–0.97death46/13130/65COVID-AIV Brown (DB RCT)−6%1.06 · 0.79–1.42death231 (n)230 (n)TESICO

Late treatment−5%1.05 · 0.63–1.7446/41330/3625% higher risk

Tau² = 0.17, I² = 82.6%, p = 0.87

All studies−5%1.05 · 0.63–1.7446/41330/3625% higher risk

Tau² = 0.17, I² = 82.6%, p = 0.8700.511.52+

Rotate screen for more detailsIncrease width for more details

← Aviptadil
reduces riskAviptadil
increases risk →

c19early.org

October 2026

Aviptadil COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Youssef (DB RCT)35%0.65 · 0.39–0.9746/13130/65COVID-AIV Brown (DB RCT)−6%1.06 · 0.79–1.42231 (n)230 (n)TESICO

Late treatment16%0.84 · 0.52–1.3546/36230/29516% lower risk

Tau² = 0.09, I² = 77.2%, p = 0.48

All studies16%0.84 · 0.52–1.3546/36230/29516% lower risk

Tau² = 0.09, I² = 77.2%, p = 0.4800.511.52+

Rotate screen for more detailsIncrease width for more details

← Aviptadil
reduces riskAviptadil
increases risk →

c19early.org

October 2026

Aviptadil COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Youssef (DB RCT)35%0.65 · 0.39–0.97death46/13130/65COVID-AIV Brown (DB RCT)−6%1.06 · 0.79–1.42death231 (n)230 (n)TESICO

Late treatment16%0.84 · 0.52–1.3546/36230/29516% lower risk

Tau² = 0.09, I² = 77.2%, p = 0.48

All studies16%0.84 · 0.52–1.3546/36230/29516% lower risk

Tau² = 0.09, I² = 77.2%, p = 0.4800.511.52+

Rotate screen for more detailsIncrease width for more details

← Aviptadil
reduces riskAviptadil
increases risk →

c19early.org

October 2026

Aviptadil COVID-19 recovery results

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Gibbs (DB RCT)−79%1.79 · 1.12–2.94no recov.51 (n)67 (n)I-SPY

Late treatment−79%1.79 · 1.10–2.8951 (n)67 (n)79% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.018

All studies−79%1.79 · 1.10–2.8951 (n)67 (n)79% higher risk

Tau² = 0.00, I² = 0.0%, p = 0.01800.511.52+

Rotate screen for more detailsIncrease width for more details

← Aviptadil
reduces riskAviptadil
increases risk →

c19early.org

October 2026

Aviptadil COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Gibbs (DB RCT)−79%1.79 · 1.12–2.94no recov.51 (n)67 (n)I-SPY Youssef (DB RCT)35%0.65 · 0.39–0.97death46/13130/65COVID-AIV Brown (DB RCT)−6%1.06 · 0.79–1.42death231 (n)230 (n)TESICO

Late treatment−5%1.05 · 0.63–1.7446/41330/3625% higher risk

Tau² = 0.17, I² = 82.6%, p = 0.87

All studies−5%1.05 · 0.63–1.7446/41330/3625% higher risk

Tau² = 0.17, I² = 82.6%, p = 0.8700.511.52+

Rotate screen for more detailsIncrease width for more details

← Aviptadil
reduces riskAviptadil
increases risk →

c19early.org

October 2026

Aviptadil COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk

Youssef (DB RCT)35%0.65 · 0.39–0.9746/13130/65COVID-AIV Brown (DB RCT)−6%1.06 · 0.79–1.42231 (n)230 (n)TESICO

Late treatment16%0.84 · 0.52–1.3546/36230/29516% lower risk

Tau² = 0.09, I² = 77.2%, p = 0.48

All studies16%0.84 · 0.52–1.3546/36230/29516% lower risk

Tau² = 0.09, I² = 77.2%, p = 0.4800.511.52+

Rotate screen for more detailsIncrease width for more details

← Aviptadil
reduces riskAviptadil
increases risk →

c19early.org

October 2026

Aviptadil COVID-19 peer reviewed studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Youssef (DB RCT)35%0.65 · 0.39–0.97death46/13130/65COVID-AIV Brown (DB RCT)−6%1.06 · 0.79–1.42death231 (n)230 (n)TESICO

Late treatment16%0.84 · 0.52–1.3546/36230/29516% lower risk

Tau² = 0.09, I² = 77.2%, p = 0.48

All studies16%0.84 · 0.52–1.3546/36230/29516% lower risk

Tau² = 0.09, I² = 77.2%, p = 0.4800.511.52+

Rotate screen for more detailsIncrease width for more details

← Aviptadil
reduces riskAviptadil
increases risk →

c19early.org

October 2026

Aviptadil COVID-19 outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk

Gibbs (DB RCT)−79%1.79 · 1.12–2.94no recov.51 (n)67 (n)I-SPY Youssef (DB RCT)35%0.65 · 0.39–0.97death46/13130/65COVID-AIV Youssef (DB RCT)20%0.80 · 0.52–1.13progression59/13131/65COVID-AIV Brown (DB RCT)−6%1.06 · 0.79–1.42death231 (n)230 (n)TESICO Brown (DB RCT)10%0.90 · 0.65–1.25progression231 (n)230 (n)TESICO

00.511.52+

Rotate screen for more detailsIncrease width for more details

← Aviptadil
reduces riskAviptadil
increases risk →